Dose escalation of second-line sunitinib results in rapid partial remission of multiple hepatic metastases
AbstractA 58-year-old man with metastatic clear cell renal cell carcinoma
on sunitinib therapy, who previously failed on sorafenib, was
found to have progression of multiple hepatic metastases; he was
on a standard sunitinib dose of 50 mg/day (4 weeks on, 2 weeks
off). Due to the unavailability of alternative therapies, a sunitinib
dose escalation of 50 mg/day was attempted. After one 6-week
cycle of continuously dosed sunitinib 50 mg, the hepatic lesions
regressed. After the second cycle, virtual disappearance of the
lesions was recorded. There was no added toxicity. These findings
suggest that sunitinib dose escalation to 50 mg/day using
continuous daily administration dosing might represent a valid,
effective and well-tolerated therapeutic option in patients who
progress on standard sunitinib therapy.
How to Cite
You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:
- Post the Article on any Web site
- Translate or authorize a translation of the Article
- Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
- Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.
The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.
You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.
The CUA also requires you to warrant the following:
- That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
- That all individuals who have made a substantive contribution to the article are acknowledged;
- That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
- That the Article does not libel or violate the privacy rights of any third party.